系统性红斑狼疮患者COVID-19疫苗接种:有效性、免疫原性、疾病复发与接种意愿的系统综述
该系统综述纳入截至2022年6月8日的32项研究(34篇报告),共8269例系统性红斑狼疮患者,评估COVID-19疫苗的有效性、免疫原性、接种意愿与安全性。汇总血清阳性率为81.1%(95%CI 72.6–88.5%,I²=85%,P<0.01),mRNA疫苗高于非mRNA疫苗;汇总接种意愿为67.0%(95%CI 45.2–85.6%,I²=98%,P<0.01)。疫苗接种后COVID-19感染、严重不良事件及中重度狼疮复发均不常见。
要点
- 汇总血清阳性率81.1%(95%CI 72.6–88.5%),mRNA疫苗高于非mRNA疫苗,异质性I²=85%。
- 汇总接种意愿67.0%(95%CI 45.2–85.6%),老年患者接种意愿更高,异质性I²=98%。
- 疫苗接种后COVID-19感染率0–17%,严重不良事件与中重度狼疮复发均不常见。
核心结论
- 在系统性红斑狼疮患者中,疫苗接种后COVID-19感染、严重复发和不良事件均不常见,而汇总血清阳性率和接种意愿较高,但存在显著异质性。
- 这些结果可为COVID-19大流行期间关于疫苗接种的共同决策提供参考。
研究设计与样本
- 系统综述,检索PubMed、EMBASE、CENTRAL和Scopus截至2022年6月8日的文献,无语种、发表年份或发表状态限制。
- 排除患者少于5例或研究结局信息不完整的报告,评估偏倚风险,并按PRISMA 2020指南报告结果。
- 共纳入32项研究(34篇报告),合计8269例系统性红斑狼疮患者。
主要发现
- 6项研究(5065例患者)报告疫苗接种后COVID-19感染率为0–17%。
- 17项研究(976例患者)评估体液免疫原性,5项研究(112例患者)评估细胞免疫原性。
- 汇总血清阳性率为81.1%(95%CI 72.6–88.5%,I²=85%,P<0.01),异质性显著,mRNA疫苗的血清阳性率高于非mRNA疫苗。
- 20项研究(3853例患者)评估不良事件,13项研究(2989例患者)评估狼疮复发,严重不良事件和中重度狼疮复发均不常见。
- 8项研究(1348例患者)的汇总疫苗接种意愿为67.0%(95%CI 45.2–85.6%,I²=98%,P<0.01),老年患者接种意愿更高。
临床怎么用
- 原文结论指出,这些结果可为COVID-19大流行期间关于疫苗接种的共同决策提供参考。
局限性
- 汇总血清阳性率存在显著异质性(I²=85%,P<0.01)。
- 汇总疫苗接种意愿存在显著异质性(I²=98%,P<0.01)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: COVID-19 infection is associated with significant morbidity in systemic lupus erythematosus but is potentially preventable by vaccination, although the impact of the myriad vaccines among SLE patients is not established. We aimed to assess the effectiveness, efficacy, acceptance and safety of COVID-19 vaccination in SLE. METHODS: We performed a systematic review of PubMed, EMBASE, CENTRAL, and Scopus publications until 8 June 2022 without language, publication year or publication status restrictions. Reports with fewer than 5 patients or incomplete information on study outcomes were excluded. Risk of bias was assessed, and results reported according to the PRISMA 2020 guidelines. RESULTS: We identified 32 studies (34 reports) comprising 8269 individuals with SLE. Post-vaccine COVID-19 infections ranged from 0 to 17% in 6 studies (5065 patients), while humoral and cellular immunogenicity was evaluated in 17 studies (976 patients) and 5 studies (112 patients), respectively. The pooled seropositivity rate was 81.1% (95% CI: 72.6, 88.5%, I2 = 85%, P < 0.01), with significant heterogeneity and higher rates for mRNA vaccines compared with non-mRNA vaccines. Adverse events and specifically lupus flares were examined in 20 studies (3853 patients) and 13 studies (2989 patients), respectively. Severe adverse events and moderate to severe lupus flares were infrequent. The pooled vaccine acceptance rate was 67.0% (95% CI: 45.2, 85.6%, I2=98%, P < 0.01) from 8 studies (1348 patients), with greater acceptance in older patients. CONCLUSION: Among SLE patients, post-vaccine COVID-19 infections, severe flares, and adverse events were infrequent, while pooled seropositivity and acceptance were high, with significant heterogeneity. These results may inform shared decision-making on vaccination during the ongoing COVID-19 pandemic. TRIAL REGISTRATION: PROSPERO, https://www.crd.york.ac.uk/PROSPERO/, CRD42021233366.
引用
- Tan SYS, Yee AM, Sim JJL, et al. COVID-19 vaccination in systemic lupus erythematosus: a systematic review of its effectiveness, immunogenicity, flares and acceptance. Rheumatology (Oxford). 2023. PMID: 36271852. doi:10.1093/rheumatology/keac604
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。